Steingrover, R., Pogány, Katalyn, Fernandez Garcia, Evian, Jurriaans, Suzanne, Brinkman, K., Schuitemaker, H., ...
Objective: An important pending question is whether temporary highly active antiretroviral therapy during primary HIV infection can influence viral rebound dynamics and the subsequently established...
Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C
Abstract Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...
Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...
Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...
Zhou, Xiao-Jian, Sommadossi, Jean-Pierre, Jurriaans, Suzanne, ...
For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy....
Baldwin, Chris E., Sanders, Rogier W., Deng, Yiqun, Jurriaans, Suzanne, Lange, Joep M., Lu, Min, ...
The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1 (HIV-1) drugs designed to block entry of the virus into the host cell. However, the success of T20 has met...
Van Der Hoek, Lia, Back, Nicole, Jebbink, Maarten F., De Ronde, Anthony, Bakker, Margreet, Jurriaans, Suzanne, ...
Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type...
Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C
Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...
Ogg, Graham S., Kostense, Stefan, Klein, Michel R., Jurriaans, Suzanne, Hamann, Dörte, McMichael, Andrew J., ...
Few studies have examined longitudinal changes in human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocytes (CTL). To more closely define the natural history of HIV-specific CTL, we...
Zhou, Xiao-Jian, Sommadossi, Jean-Pierre, Jurriaans, Suzanne, ...
For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy....
Baldwin, Chris E., Sanders, Rogier W., Deng, Yiqun, Jurriaans, Suzanne, Lange, Joep M., Lu, Min, ...
The fusion inhibitor T20 belongs to a new class of anti-human immunodeficiency virus type 1 (HIV-1) drugs designed to block entry of the virus into the host cell. However, the success of T20 has met...
Van Der Hoek, Lia, Back, Nicole, Jebbink, Maarten F., De Ronde, Anthony, Bakker, Margreet, Jurriaans, Suzanne, ...
Resistance to antiretroviral drugs is generally conferred by specific amino acid substitutions, rather than insertions or deletions, in reverse transcriptase (RT) of human immunodeficiency virus type...
Cornelissen, Marion, Jurriaans, Suzanne, Prins, Jan M, Bakker, Margreet, Van Der Kuyl, Antoinette C
Partial or complete seroreversion for HIV-1, or incomplete antibody evolution are relatively rare events that have so far only been described in patients treated with HAART early after virus...
Pasternak, Alexander O., Adema, Karen W., Bakker, Margreet, Jurriaans, Suzanne, Berkhout, Ben, Cornelissen, Marion, ...
The effectiveness of highly active antiretroviral therapy (HAART), the standard of care for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, is assessed by measuring the viral...